Clinical Trials Logo

Clinical Trial Summary

The influences of diet on psoriasis have been long discussed. As reported in previous publications, a majority of U.S. psoriasis population show high interest in the role of diet on their skin conditions. Given the distinct traditional perceptions and lifestyles in China, the dietary beliefs and behaviors in Chinese psoriasis patients would be very likely to show different patterns. Nevertheless, the information of this large population is still unknown. In this regard, the investigators conduct a questionnaire-based survey, aiming to assess the dietary perceptions and behaviors of Chinese psoriasis patients.


Clinical Trial Description

A total of 25 medical institutions all over China participated in the survey. Psoriasis patients surveyed were from both outpatient and inpatient dermatology departments. Researchers from each institution were trained for assisting patients to fill the questionnaire. Each participant filled the online-based questionnaire anonymously in a private setting. The questionnaire consisted of 54 main questions and extended questions, concerning the profile of disease conditions, perceptions and behaviors of diet in their daily life. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05118425
Study type Observational
Source Xijing Hospital
Contact
Status Completed
Phase
Start date November 1, 2020
Completion date September 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT03236870 - A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
Completed NCT00078819 - Etanercept (Enbrel®) in Psoriasis - Pediatrics Phase 3
Recruiting NCT04841187 - Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
Active, not recruiting NCT03927352 - The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis Phase 3
Active, not recruiting NCT03284879 - Post-Marketing Surveillance Study of OTEZLA
Recruiting NCT04149587 - A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
Completed NCT01384630 - Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis Phase 2
Active, not recruiting NCT03998683 - A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis Phase 3
Recruiting NCT03556202 - A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) Phase 3
Recruiting NCT05051943 - A Prospective Observational Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT04316585 - A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants Phase 1
Completed NCT00358384 - Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034 Phase 1
Completed NCT03757013 - A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
Not yet recruiting NCT05065762 - Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment
Active, not recruiting NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Active, not recruiting NCT05003531 - A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis Phase 2
Active, not recruiting NCT04603027 - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis Phase 2
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Not yet recruiting NCT04535999 - Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV) Phase 4
Not yet recruiting NCT04630652 - Risankizumab Long-term Remission Study Phase 4